ARPA-H awarded up to $125 million under its GIVE program to build a domestic, automated network for producing individualized, on-demand RNA-based genetic medicines with testing capacity near the point of care. The plan targets lower costs and integrated quality-control workflows embedded in the manufacturing process. The awardees include teams led by Massachusetts General Hospital, Centillion Biosciences, HDT Bio, Waterfall Scientific, and University of Utah. Each team is tasked with specific components—ranging from single-use, all-fluidics chip manufacturing systems and cartridge-based RNA/DNA production to autonomous quality control and same-day testing platforms. The initiative signals a shift from platform prototypes toward scalable, repeatable manufacturing architectures that can support decentralized production models and faster iterative validation of both RNA synthesis and release testing.